onlinecasinoslotsrealmoney| Luoxin Pharmaceutical: Phase III clinical study of plkanatide tablets reached the primary efficacy endpoint
Tonghuashun (300033) Financial Research Center, April 15onlinecasinoslotsrealmoney, some investors asked Luo Xin Pharmaceutical (002793) how long has the company's new drug capnantide been conducting phase III trials? How is it going so far?
The company replied, Hello, Dear Investor! The Phase III clinical study of procanatide tablets has reached the main efficacy endpoint. For details, please refer to the company's "Luoxin Pharmaceutical: Announcement on the Progress of Phase III Clinical Study of procanatide tablets" disclosed by Juchao Information Network on January 27, 2024. Thank you for your attention!